--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-26-272814" form_type: "8-K" ticker: "SLN" cik: "0001479615" company_name: "Silence Therapeutics plc" filed_at: "2026-06-16T21:00:17+00:00" generated_at: "2026-06-16T21:02:59.337375+00:00" event_type: "other" sentiment: "neutral" materiality_score: 0.1 calibrated_materiality_score: 0.1 confidence: "high" source: SEC EDGAR --- # All 9 resolutions pass at Silence Therapeutics 2026 AGM including director re-elections and say-on-pay ## Summary - Both director nominees re-elected: Rhonda Hellums (47.2M for, 5.6M against) and James Ede-Golightly (52.1M for, 0.6M against). - Advisory say-on-pay approved with 48.2M votes for, 73.7K against, and 4.4M abstentions. - Ratification of PricewaterhouseCoopers as US and UK auditors passed with ~52.7M votes for. - Directors' remuneration report for 2025 approved: 48.3M for, 66.5K against, 4.4M abstentions. ## SEC filing metadata - accession: 0001193125-26-272814 - form_type: 8-K - ticker: SLN - cik: 0001479615 - company_name: Silence Therapeutics plc - filed_at: 2026-06-16T21:00:17+00:00 - event_type: other - sentiment: neutral - materiality_score: 0.1 - calibrated_materiality_score: 0.1 - confidence: high - sec_items: 5.07 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/0001193125-26-272814-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/sln-20260616.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-26-272814 - JSON: https://secwatch.observer/filing/0001193125-26-272814.json - Plain text: https://secwatch.observer/filing/0001193125-26-272814.txt ## Key facts - Shareholder Votes Silence Therapeutics plc shareholders approved To approve the directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 32 to 54 (inclusive) of the 2025 U.K. Annual Report. at the 2026-06-16 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-16 source text: Resolution 8 : To approve the directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 32 to 54 (inclusive) of the 2025 U.K. Annual Report. The votes were cast as follows: For Against Abstain 48,251,875 66,518 4,404,018 evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/0001193125-26-272814-index.htm - Shareholder Votes Silence Therapeutics plc shareholders approved To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). at the 2026-06-16 meeting. - Outcome: passed - Meeting: 2026-06-16 source text: Resolution 7 : To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). The votes were cast as follows: For Against Abstain 52,715,076 3,108 4,077 evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/0001193125-26-272814-index.htm - Shareholder Votes Silence Therapeutics plc shareholders approved To approve the application of Article 159 of the Company's articles of association from the conclusion of this AGM to the conclusion of the next annual general meeting of the Company. at the 2026-06-16 meeting. - Outcome: passed - Meeting: 2026-06-16 source text: Resolution 9 : To approve the application of Article 159 of the Company's articles of association from the conclusion of this AGM to the conclusion of the next annual general meeting of the Company. The votes were cast as follows: For Against Abstain 48,307,317 9,333 4,405,761 evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/0001193125-26-272814-index.htm - Shareholder Votes Silence Therapeutics plc shareholders approved To authorize the Audit & Risk Committee to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2026. at the 2026-06-16 meeting. - Outcome: passed - Meeting: 2026-06-16 source text: Resolution 6 : To authorize the Audit & Risk Committee to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 52,714,237 6,155 1,869 evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/0001193125-26-272814-index.htm - Shareholder Votes Silence Therapeutics plc shareholders approved To re-appoint as a director of the Company Rhonda Hellums. at the 2026-06-16 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-06-16 source text: Resolution 1 : To re-appoint as a director of the Company Rhonda Hellums. The votes were cast as follows: For Against Abstain 47,160,731 5,557,090 4,680 evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/0001193125-26-272814-index.htm - Shareholder Votes Silence Therapeutics plc shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-16 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-06-16 source text: Resolution 4 : To ratify the appointment of PricewaterhouseCoopers LLP as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 52,718,407 2,885 1,119 evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/0001193125-26-272814-index.htm - Shareholder Votes Silence Therapeutics plc shareholders approved To re-appoint as a director of the Company James Ede-Golightly. at the 2026-06-16 meeting. - Proposal: director election - Outcome: passed - Meeting: 2026-06-16 source text: Resolution 2 : To re-appoint as a director of the Company James Ede-Golightly. The votes were cast as follows: For Against Abstain 52,112,045 605,683 4,680 evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/0001193125-26-272814-index.htm - Shareholder Votes Silence Therapeutics plc shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. at the 2026-06-16 meeting. - Proposal: say on pay - Outcome: passed - Meeting: 2026-06-16 source text: Resolution 3 : To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: For Against Abstain 48,234,208 73,667 4,414,536 evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/0001193125-26-272814-index.htm - Shareholder Votes Silence Therapeutics plc shareholders approved To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. at the 2026-06-16 meeting. - Proposal: auditor ratification - Outcome: passed - Meeting: 2026-06-16 source text: Resolution 5 : To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. The votes were cast as follows: For Against Abstain 52,718,407 2,885 1,119 evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/0001193125-26-272814-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.